GSA Capital Partners LLP Boosts Position in Tenaya Therapeutics, Inc. $TNYA

GSA Capital Partners LLP lifted its stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 220.2% during the 4th quarter, Holdings Channel reports. The fund owned 1,478,612 shares of the company’s stock after buying an additional 1,016,808 shares during the quarter. GSA Capital Partners LLP’s holdings in Tenaya Therapeutics were worth $1,052,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Woodline Partners LP increased its position in shares of Tenaya Therapeutics by 30,563.2% during the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company’s stock worth $3,373,000 after purchasing an additional 5,896,873 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Tenaya Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,064,857 shares of the company’s stock worth $8,205,000 after purchasing an additional 309,530 shares during the last quarter. Millennium Management LLC increased its position in shares of Tenaya Therapeutics by 561.7% during the 3rd quarter. Millennium Management LLC now owns 4,504,592 shares of the company’s stock worth $7,297,000 after purchasing an additional 3,823,848 shares during the last quarter. Two Sigma Investments LP increased its position in shares of Tenaya Therapeutics by 91.8% during the 3rd quarter. Two Sigma Investments LP now owns 910,568 shares of the company’s stock worth $1,475,000 after purchasing an additional 435,781 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in Tenaya Therapeutics in the 1st quarter valued at about $442,000. 90.54% of the stock is owned by institutional investors and hedge funds.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $0.79 on Friday. The business’s fifty day moving average price is $0.77 and its 200 day moving average price is $0.87. Tenaya Therapeutics, Inc. has a 1-year low of $0.39 and a 1-year high of $2.35. The firm has a market capitalization of $171.43 million, a PE ratio of -1.68 and a beta of 2.77.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $7.50 million. Equities research analysts expect that Tenaya Therapeutics, Inc. will post -0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Leerink Partners reaffirmed an “outperform” rating and issued a $2.00 target price on shares of Tenaya Therapeutics in a research report on Thursday, March 12th. Chardan Capital reissued a “buy” rating and set a $8.00 price objective on shares of Tenaya Therapeutics in a research report on Thursday, March 12th. William Blair restated an “outperform” rating on shares of Tenaya Therapeutics in a research note on Thursday, March 12th. Wall Street Zen upgraded Tenaya Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Lifesci Capital upgraded Tenaya Therapeutics to a “strong-buy” rating in a research note on Thursday, March 5th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tenaya Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $4.00.

Insiders Place Their Bets

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $0.56, for a total value of $1,966,622.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 4,178,262 shares of company stock valued at $2,381,172 over the last quarter. 2.53% of the stock is currently owned by corporate insiders.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.